BOULDER, Colorado–(BUSINESS WIRE)–Enveda Biosciences today announced the appointment of Mark Deeg, MD, Ph.D., as the company’s Chief Medical Officer. Dr. Deeg is a medical and pharmaceutical leader with extensive experience developing digital drugs and therapies at companies ranging from biopharmaceutical startups to pharmaceutical giants like Eli Lilly & Co., where he spent over a decade.
“We are delighted to welcome Mark Deeg to Enveda as Chief Medical Officer,” said Viswa Colluru, Ph.D., Founder and CEO of Enveda. “Mark’s experience in all phases of drug discovery and development, including building and advancing diverse pipelines and pioneering novel approaches, is an excellent complement to our immediate goals as well as to our long-term vision. We look forward to Mark’s insight, industry knowledge and leadership. »
Dr. Deeg joins Enveda from Cullgen Inc., where he was Executive Vice President and Head of Global Clinical Development. He was responsible for overseeing the development of PROTACs for oncology, pain and immunology applications, and providing strategic direction for target selection and clinical indications for each asset.
Prior to his tenure at Cullgen, Mark held senior medical and research positions in companies focused on digital and mRNA therapies. He has developed digital therapies from concept to clinical trials, including the design and implementation of a decentralized clinical trial. He also developed two mRNA therapies for kidney disease, both in orphan indications, conducting a proof-of-concept study for one and advancing the second from candidate selection to Phase I.
“It’s an exciting time at Enveda and I’m grateful to have the chance to join the team and help advance a growing number of interesting compounds,” said Dr. Deeg. “Enveda’s Discovery Platform is remarkable, not only because of the technology, but also because of the remarkable people. The quality of Enveda’s people was a strong recurring theme when I got to know the company. I am happy to be able to bring my 30 years of experience to a company that has made so much progress in such a short time, and which is committed to excellence and leadership in the field.
Dr. Deeg also spent more than a decade at Eli Lilly & Co., including serving as Medical and Safety Director of Chorus, a division of Lilly Research Laboratories. He has overseen the clinical development of 23 compounds, from candidate screening to proof of concept, including Phase II and IND submissions.
At Lilly, Dr. Deeg’s functional responsibilities covered all of drug discovery and development, including responsibility for the development and implementation of biomarker strategies for Phase I-IV studies for the endocrine portfolio. from Lilly. He also led clinical teams advancing two small molecule compounds from preclinical to Phase II, two small molecules and one large molecule from preclinical to Phase I, and initiated a Phase Ib/proof of concept for an additional large molecule compound. .
Dr. Deeg earned his Ph.D. in pharmacology from the University of Minnesota Twin Cities and his MD from the University of Minnesota Medical School.
About Enveda Biosciences
Enveda Biosciences is a biotechnology company building the first high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery. Enveda’s platform is the world’s most advanced drug discovery search engine for the nearly limitless breadth of nature’s unknown chemistry, building on years of cutting-edge advances at the intersection metabolomics and machine learning. Complementing its breakthrough technology, Enveda’s team includes seasoned drug hunters with decades of pharmaceutical industry experience working alongside world-renowned data scientists. For more information about Enveda, visit envedabio.com.